Humacyte, Inc. (NASDAQ:HUMA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA) have received an average recommendation of “Moderate Buy” from the eight analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $7.7143.

A number of analysts recently commented on HUMA shares. Wall Street Zen downgraded shares of Humacyte from a “hold” rating to a “sell” rating in a report on Sunday, December 21st. BTIG Research decreased their price objective on shares of Humacyte from $6.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, March 27th. Benchmark decreased their price objective on shares of Humacyte from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, January 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Humacyte in a report on Monday, December 29th. Finally, D. Boral Capital reissued a “buy” rating and set a $25.00 price objective on shares of Humacyte in a report on Friday, March 27th.

Institutional Trading of Humacyte

A number of institutional investors have recently added to or reduced their stakes in HUMA. Marshall Wace LLP boosted its holdings in Humacyte by 5,308.2% during the second quarter. Marshall Wace LLP now owns 2,639,194 shares of the company’s stock worth $5,516,000 after buying an additional 2,590,394 shares in the last quarter. Millennium Management LLC boosted its holdings in Humacyte by 129.5% during the fourth quarter. Millennium Management LLC now owns 2,631,990 shares of the company’s stock worth $2,528,000 after buying an additional 1,485,152 shares in the last quarter. UBS Group AG lifted its holdings in shares of Humacyte by 48.8% in the fourth quarter. UBS Group AG now owns 2,978,610 shares of the company’s stock valued at $2,862,000 after purchasing an additional 976,275 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Humacyte by 33.4% in the second quarter. Geode Capital Management LLC now owns 2,948,508 shares of the company’s stock valued at $6,163,000 after purchasing an additional 738,142 shares in the last quarter. Finally, Barclays PLC lifted its holdings in shares of Humacyte by 298.7% in the fourth quarter. Barclays PLC now owns 729,469 shares of the company’s stock valued at $701,000 after purchasing an additional 546,491 shares in the last quarter. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Trading Down 6.6%

Shares of Humacyte stock opened at $0.61 on Wednesday. Humacyte has a 52-week low of $0.55 and a 52-week high of $2.93. The company has a quick ratio of 0.90, a current ratio of 3.69 and a debt-to-equity ratio of 20.08. The company’s 50-day simple moving average is $0.98 and its 200-day simple moving average is $1.23. The firm has a market cap of $134.74 million, a price-to-earnings ratio of -3.03 and a beta of 2.11.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings results on Friday, March 27th. The company reported ($0.13) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.13). Humacyte had a negative net margin of 1,998.87% and a negative return on equity of 990.48%. The business had revenue of $0.47 million for the quarter, compared to analyst estimates of $1.35 million. As a group, equities research analysts anticipate that Humacyte will post -1.27 earnings per share for the current year.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.